New Delhi: One of India’s leading anti-diabetic players, USV, has become the latest entrant in the Empagliflozin generic contest with the launch of its version, Xenia, in India.
The Indian drug maker has introduced the generic version under the brand names: Xenia (Empagliflozin 10 mg & 25 mg), Xenia M (Empagliflozin 12.5 mg + Metformin 500 mg IR / 1000 mg ER), Xenia ST (Empagliflozin 25 mg + Sitagliptin 100 mg).
“With Xenia, we aim to expand access to modern diabetes care while reinforcing our leadership in the segment. USV remains committed to delivering affordable, high-quality therapies for better patient outcomes,” said Prashant Tewari, Managing Director, USV.
Xenia (Empagliflozin and its combinations) is an SGLT2 inhibitor indicated for glycemic control, heart failure, and chronic kidney care in people with Type 2 diabetes.
In a release, the company stated, “These combinations offer flexible dosing, reduced pill burden, and improved access to modern therapy, enabling early treatment to reduce diabetes complications and mortality.”
According to the company, the Indian SGLT2 drug market is valued at approximately ₹1,100 crore, and USV aims to strengthen its presence through its extensive distribution network.
The innovator’s patent for Empagliflozin expired earlier this month, following which several Indian brands, including Alkem, Mankind, and Glenmark, launched their generic versions in the market.
Additionally, other pharma players like Torrent, Lupin, and several others are expected to soon roll out their own generic versions.
For patients, this development has provided significant cost relief, with generic versions estimated to cost 80–90 per cent less than the patented version.
